Compare · NSRX vs NVO
NSRX vs NVO
Side-by-side comparison of Nasus Pharma Ltd. (NSRX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NSRX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $172.11B, about 5763.5x NSRX ($29.9M).
- NVO has been more active in the news (9 items in the past 4 weeks vs 8 for NSRX).
- NVO has more recent analyst coverage (25 ratings vs 0 for NSRX).
- Company
- Nasus Pharma Ltd.
- Novo Nordisk A/S
- Price
- -
- $38.66-0.63%
- Market cap
- $29.9M
- $172.11B
- 1M return
- -
- -0.41%
- 1Y return
- -
- -18.26%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NYSE
- IPO
- 2025
- News (4w)
- 8
- 9
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NSRX
- SEC Form 3 filed by new insider Nir Sassi
- Nasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe Nasal Congestion
- SEC Form 4 filed by Interim CFO Elmaliah Oren
- SEC Form 6-K filed by Nasus Pharma Ltd.
- Nasus Pharma Appoints Nir Sassi as Chief Financial Officer
- Amendment: SEC Form SCHEDULE 13G/A filed by Nasus Pharma Ltd.
- Chief Executive Officer O'Grady Brendan P. was granted 210,000 share options (SEC Form 4)
- Nasus Pharma Announces Abstracts Accepted for Presentation at ACAAI 2026
- SEC Form S-8 filed by Nasus Pharma Ltd.
- SEC Form 6-K filed by Nasus Pharma Ltd.
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S